SCHEMBL27123592

SCHEMBL27123592

Cn1ncc2cccc(NS(=O)(=O)c3ccc(Cl)nc3)c21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.55
▸ LMNA P02545 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ SLC40A1 Q9NP59 8/20 0.46
▸ CCR2 P41597 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ CCR4 P51679 2/20 0.43
▸ PTPN11 Q06124 1/20 0.41
▸ MITF O75030 1/20 0.40
▸ S1PR4 O95977 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ S1PR1 P21453 1/20 0.40
▸ AGTR1 P30556 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CKS1B P61024 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30846193 1.00 GAA (0.55) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL27119245 0.93 GAA (0.48) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL30846339 0.84 SLC40A1 (0.42) GAALMNASLC40A1ALDH1A1KMT2A
SCHEMBL27154161 0.84 SLC40A1 (0.42) GAALMNASLC40A1ALDH1A1KMT2A
SCHEMBL30846168 0.83 GAA (0.55) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL27125947 0.83 GAA (0.55) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL30846236 0.83 LMNA (0.50) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL27123808 0.83 LMNA (0.50) GAALMNAMAPK1SLC40A1CCR2
SCHEMBL30846478 0.83 TDP1 (0.41) GAALMNAMAPK1SLC40A1ALDH1A1
SCHEMBL27126473 0.83 TDP1 (0.41) GAALMNAMAPK1SLC40A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B GAA 2769/4885LMNA 2121/4885MAPK1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback